A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Podejrzenie glejaka mózgu potwierdzone badaniami obrazowymi
- •Planowana operacja usunięcia guza
- •Dobrowolna zgoda na udział w badaniu
- •Podpisana zgoda na badania genetyczne
✗ Disqualifies
- •Osoby pod opieką prawną lub nadzorem
- •Stosowanie leków obniżających odporność
- •Ciąża lub karmienie piersią
- •Osoby pozbawione wolności przez sąd lub służby publiczne
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
CHU de Bordeaux
Bordeaux, France
Trial contact
Julien ENGELHARDT, Dr
Olivier BRANCHARD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.